Skip to main content

Advertisement

Table 4 Comparison of patients’ characteristics and elimination efficacy

From: First clinical experience in 14 patients treated with ADVOS: a study on feasibility, safety and efficacy of a new type of albumin dialysis

Trial/Reference Banares [10] Kribben [19] Sponholz MARS [7] Sponholz SPAD [7] Own study
Device MARS Prometheus MARS SPAD ADVOS
Patients’ characteristics
 Clinical setting 19 ICUs 10 ICUs Surgical ICU Medical ICU
  Type of LF     
  - ACLF 100% 100% 56% 64%
  - ALF - - 28% -
  - “secondary” LF - - - 36%
  - Graft failure - - 16% -
 (CLIF)-SOFA 8 ± 3 10 ± 3 13 ± 4 15 ± 3
 MELD 26 ± 8 28 ± 10   34 ± 7
 Child-Pugh 11 ± 2 12 ± 1   12 ± 1
Efficacy analysis
 No. of treatments for efficacy analysis 4 8 (mean) 2.2 (mean) 2.2 (mean) 1
 Delta-Bilirubin relative −26% (day 4) −23% (day 28) −23% −23% −32%
 Delta-Bilirubin absolute [mg/dL] −8.7 (day 4) −6 (day 28) −4.3 −4.2 −8.3
 Delta-creatinine relative −20% (day 4) −13% (day 28) −18% +5% −27%
 Delta-creatinine absolute [mg/dL] −0.3 (day 4) −0.2 (day 28) −0.4 +0.1 −0.6
 Delta-BUN relative n.d. n.d. −9% +5% −37%
 Delta-BUN absolute [mg/dL] n.d n.d. −12 +8 −18
 Maximum number of treatments 10 11 4 4 101